Mason Kauffman, President, Chief Executive Officer, Board Chairman
Kauffman received his BS from the University of Michigan and MBA from the University of Memphis. He was part of FedEx’s pioneering teams from 1978-1994 before leaving to found, grow, and sell his own businesses. Those companies, Express Logistics and Accuship, earned Inc. Magazine’s 500 Fastest Growing Company status. Kauffman was recognized as Entrepreneur of the Year by Ernst & Young, as an industry “mover and shaker” by Bloomberg Businessweek, and as a “leader in the pack” by LEADERS Magazine.
Chris Przybyszewski, Executive Vice President, Board Secretary
Przybyszewski earned his BA from the University of Pennsylvania and his MA from the University of Memphis. He has spent his career working with physicians and scientists in the neuroscience, medical device, and vaccines fields, where he has helped them translate basic technologies into implementable programs and products. By providing strategic planning and implementation expertise, Przybyszewski has helped build multi-national public-private programs funded by government, foundation, and industry partners.
Steve Zatechka, PhD, MBA, Chief Science Officer
Dr. Zatechka earned his PhD from the University of Nebraska Medical Center and his MBA from the University of Memphis. He completed his postdoctoral fellowship with the Howard Hughes Medical Institute at St. Jude Children’s Research Hospital. Dr. Zatechka is experienced in the development and utilization of gene targeting technologies for animal models and the development of applied biotechnology-based protocols. Dr. Zatechka is the inventor of US BIOLOGIC’s patented production platform technology.
Colonel (ret) Tom Monath, MD, Board Director
Dr. Monath received his AB degree from Harvard College and his MD from Harvard Medical School and currently serves as Managing Partner and Chief Scientific Officer of Crozet Biopharma. He is an internationally recognized virologist and vaccinologist with over 50 years’ experience in research on viral and bacterial diseases, twenty-five of which have been in the vaccines industry. His expertise spans discovery research and all functional areas of product development. He has worked in leadership positions in US government agencies and in the biotechnology sector. He had primary responsibility for bringing multiple innovative vaccines into clinical development, including Ebola Zaire, cell-based smallpox, dengue, Japanese encephalitis, West Nile, cytomegalovirus, influenza, live and inactivated yellow fever, Helicobacter pylori, Clostridium difficile, four of which are now licensed and commercialized.
Before forming Crozet, Dr. Monath was CSO and COO of BioProtection Systems, the infectious disease subsidiary of NewLink Genetics, where he led the development of the recombinant vesicular stomatitis vectored Ebola vaccine funded by BARDA and DTRA in partnership with Merck, and he initiated and led development efforts on a new Zika vaccine.
Prior, Dr. Monath was Chief Medical Officer of Hookipa Biotech, Juvaris and Xcellerex and CSO and an Executive Director of Acambis before its acquisition by Sanofi Pasteur. In that position he developed a novel platform for vaccine development (ChimeriVax™) and brought three human and one veterinary vaccine through regulatory approval, including ACAM2000® smallpox vaccine under $500m development and procurement contracts from HHS.
Along with his duties at US BIOLOGIC, Dr. Monath currently serves on the boards of Juvaris Inc. and Sentinext Plc and on the Scientific Advisory Boards of RapidMicro Biosystems, GeoVax and SutroVax. Between 2006-2012, Dr. Monath was a Partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm where oversaw investments in the vaccine space. Before joining industry, Dr. Monath served in the uniformed services of US Public Health Service and the US Army for twenty-four years, retiring as a Colonel. During that time Dr. Monath served as Director, Division of Vector-Borne Viral Diseases at the Centers for Disease Control and Prevention and Chief, Virology Division at the US Army Medical Research Institute of Infectious Diseases.
He has received many prestigious awards, including the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), the Walter Reed Medal (2002) and the James H. Steele Gold-Headed Cane Award (2015). He has served on numerous government and international committees on infectious diseases, biosecurity, WHO expert committees and the National Vaccines Advisory Committee (USA), and is Past-President of the American Society of Tropical Medicine and Hygiene and an elected Fellow of the Society. He has been a leader in and founding member of the One Health Initiative and is an expert in arthropod-borne viruses. He has published over 425 scientific papers and six books on virology and vaccine development and has thirty-five patents.
Michael Shmerling, Board Member
Shmerling received his Bachelor of Accountancy degree from the University of Oklahoma and is a veteran entrepreneur who has established and grown profitable companies in a wide spectrum of industries, including finance, consumer products, and corrections, among others.
Shmerling began his career as a CPA with Ernst & Young and has since founded five businesses, four of which were acquired by publicly traded companies. At present, Shmerling serves as Chairman of Clearbrook Holdings Corp., a management and investment holding company. In addition, Shmerling serves on the board of several companies including Choice Food Group, Inc., Maynard Select, LLC, and Health Connect America, Inc. In 2007, he was awarded the American Institute of CPA’s Public Service Award.
Gov. Tommy Thompson, Board Member
Gov. Thompson served as Wisconsin’s governor for fourteen years, focusing on the revitalization of the state’s economy. Through these efforts, Gov. Thompson gained national attention for his leadership on welfare reform, expanding access to health care for low-income people, and education. In 2001, Gov. Thompson accepted the nomination for U.S. Secretary of Health and Human Services.
As the nation’s leading advocate for the health and welfare of all Americans, Gov. Thompson led the department which employed more than 60,000 personnel and had a fiscal year 2001 budget of $429 billion. Gov. Thompson now serves on several strategic healthcare-related boards and served as the Chairman of Deloitte’s Global Healthcare Practice focusing on Health Care Management and Transformation.
Dave Williams, Board Member
Williams holds a degree in Accounting and Management from Scranton University and retired in 2008 as Chairman & CEO of Sanofi Pasteur, the vaccines business of Sanofi-Aventis Group. Williams’ thirty years with the company was marked by his rise from Finance Manager, to General Manager of the US Business unit, to being named the company’s U.S. President of the company. He was later named Global President & COO in 1998. Williams’ leadership moved the company from a niche vaccine business to the global leader in vaccine development, production, and sales, with 2007 revenues of more than US $6 billion. Sanofi Pasteur is the largest vaccine business in the world and but also provides the broadest range of vaccines available from a single company.
Under Williams’ guidance, more than one billion doses of Sanofi Pasteur’s lifesaving vaccines were administered to more than 500 million people around the world each year, representing more than 25% of the global vaccine market. The company grew to almost 13,000 employees, licensed more than 30 new vaccines and launched hundreds of business development programs under Williams’ leadership.
Luciana Meirelles Richer, DVM, MSc, Principal Scientist & Laboratory Director
Dr. Richer earned her DVM from State University of Sao Paulo, Brazil and MSc in Veterinary Sciences from Federal University of Rio Grande do Sul, Brazil. She has worked on oral vaccine projects against Lyme disease and other infectious diseases with Dr. Maria Gomes-Solecki, as well as several ground-breaking methodologies for tick-borne disease diagnostic tools.
Dr. Richer brings vast animal model experience for vaccine delivery and diagnostics, as well as great expertise in microbiology and immunology. She is the lead author on several pivotal publications, including Reservoir Targeted Vaccine Against Borrelia burgdorferi: A New Strategy to Prevent Lyme Disease Transmission.
Ed Robb, DVM, Senior Product Development & Regulatory Affairs
Dr. Robb earned his BS and DVM from Cornell University and subsequently served as a veterinarian in New York. Following his interest in research and large-scale solutions to health problems, Dr. Robb attended the University of Pennsylvania, earning his MS in Epidemiology and completed a residency in Clinical Nutrition. Dr Robb is a Diplomat in the American College of Veterinary Nutrition.
Dr. Robb has influenced the research and commercialization of animal health products for over thirty years and has been actively engaged in global product development. He quickly became a strategic innovation leader in several of the industry’s largest companies, including Upjohn, Pharmacia, Pfizer, Boehringer-Ingelheim Vetmedica, Ceva, and Parnell Pharmaceuticals.
Dr. Robb’s career can be highlighted by bringing innovative products in a myriad of therapeutic areas through Proof of Concept, pivotal clinical trials, regulatory approval and into global markets.
Robb and his teams were responsible for novel drugs like Naxcel®, Excenel®, Excede® and Spectamast®, with annual global sale of more than $250M, and other products highlighting CIDR®, Pirsue®, Presponse®, ProZinc®, Prascend®, Palladia®, Trocoxil®, Duramune Ultra®, Oral Bb®, Improvest®, Vetera® equine vaccines, J-5®, Antirobe®, Simplecef® and a novel anthelmintic.
Dr. Wikel received a Ph.D. from the University of Saskatchewan and went on to serve as a staff fellow at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, as well as Professor and Acting Chair, Department of Immunology, School of Medicine, University of Connecticut. He subsequently served as Professor of Pathology, University of Texas Medical Branch and Senior Scientist at the Center for Tropical Diseases and Center for Biodefense and Emerging Infectious Diseases, Galveston National Laboratory.
In 2011, Dr. Wikel was appointed Senior Associate Dean, Professor and Chairman, Department of Medical Sciences, and St. Vincent’s Medical Center Endowed Chair, School of Medicine, Quinnipiac University, as one of four deans to establish a new school.
Dr. Wikel has led worldwide research collaborations in tick physiology and genetic discovery research, as well as host immunological responses and vector countermeasures to host defenses at the arthropod vector-host-pathogen interface; the role of those interactions on blood feeding and pathogen transmission; and, development of novel immune-based anti-vector and pathogen transmission blocking control strategies.
Dr. Wikel has ninety-one peer reviewed publications and sixteen invited review and book chapters on these topics. He has been a featured speaker for seventy-five national and international symposia. Dr. Wikel received extramural research support for his program from the National Institutes of Health, U.S. Army Medical Research and Materiel Command, Centers for Disease Control and Prevention, U.S. Department of Agriculture and industry. He has extensive service experience as a member of advisory panels, research study sections, editorial boards and academic institution administration.
Maria Gomes-Solecki, DVM, Inventor
Dr. Gomes-Solecki earned her DVM from the University of Lisbon, completed a Fellowship at the National Institute of Technology, Lisbon, Portugal, and her post-doctorate work at Stony Brook University.
She is now an Associate Professor of Microbiology and Immunology, University of Tennessee Health Science Center, serves as president of Immuno Technologies, and is the inventor of US BIOLOGIC’s first oral vaccination technology. In 2014, Dr. Gomes-Solecki was recognized as the “Innovator of the Year” by MBQ Magazine.
Steve Good, Senior PMP and T&O Advisor
Good received his BA in Economics from the University of Memphis and has since become one of the pest-management industry’s leading marketing and sales executives with a focus on bringing new products to market, expanding national markets, and M&A activities. In his executive leadership roles at Terminix, Good provided sales leadership, business strategy development, brand positioning, direct marketing, media advertising, public relations, promotions, and product placement across multiple verticals.
Good oversaw the successful integration of these business development strategies to help propel Terminix to their industry leadership position while overseeing a $60M annual marketing budget, managing a global sales force of over 1,500, and generating over $500,000,000 in annualized sales.
Louise Henderson, PhD, USDA/CVB Consultant
Dr. Henderson received her BS, MS, and Ph.D., Molecular, Cellular, & Developmental Biology from the Iowa State University and later served as a manager in PEL at the USDA APHIS CVB as a manager in PEL in 2008 and has since been a consultant in veterinary biologics. She served as Chief of Biotechnology, Immunology, and Diagnostics.
She was responsible for overseeing policy, laboratory testing, and review and approval of licensing submissions for all biotechnology, immunology, and diagnostic products. She also has expertise in regulatory jurisdiction issues for those products that may be either a veterinary biologic regulated by the USDA or a veterinary drug regulated by the FDA.
AdaMae Lewis, PhD, USDA/CVB Consultant
Dr. Lewis left the CVB as a manager in IC in 1994 and has since been a consultant in veterinary biologics. She has extensive experience and expertise in facilities inspection and requirements for licensing and permitting of veterinary biologics. She has facilitated the Institute for International Cooperation in Animal Biologics (IICAB) Training since it began in 1996. Dr. Lewis guides US BIOLOGIC in all areas related to Inspection and Compliance (IC). IC is responsible for inspection and approval of facilities and productions records, approval of release of serials of veterinary biologics, and compliance with USDA regulations.
Sanford Kaufman, Senior Political Advisor
Mr. Kaufman has Master Degrees in both Biology and Public Administration, from St. John’s University and New York University, respectively. He has over twenty years’ experience leading the State Government Affairs function at Sanofi Pasteur, the vaccine subsidiary of Sanofi Aventis. Over that time, Kaufman led lobbying and public policy initiatives in over 40 states and interacted with major policy organizations in the public health arena. Sanford advises US BIOLOGIC management and board leaders on all state efforts, helps coordinate lobbyist activities, and ensure full compliance with all state lobbyist regulations.
Major General (ret) William K. Suter, Political Advisor
Receiving his BA degree from Trinity University and his JD degree from Tulane University School of Law, Gen. Suter has served in numerous positions of responsibility around the world, including Appellate Judge, Deputy Staff Judge Advocate of the U.S. Army Vietnam, Staff Judge Advocate of the 101st Airborne Division, Commandant of the JAG School, and the Assistant Judge Advocate General of the Army.
Most recently, Gen. Suter has recently retired as the 19th Clerk of the Supreme Court of the U.S. where he served for twenty-two years. Gen. Suter also served as Army Judge Advocate before retiring as a Major General. Gen. Suter provides US BIOLOGIC with governmental agency and military leadership insights and guidance.
Colonel (ret) Steven Swann, MD, FACS, Senior Medical Advisor
Following thirty-four years of service as an Army Physician, Col. Swann retired as Command Surgeon, US Special Operations Command (USSOCOM). In this role, Col. Swann served as the Senior Physician for all of the Department of Defense’s Special Operations Forces worldwide. Previously, Col. Swann served as Commander of the 3,000-man 30th Medical Brigade, US Army Europe (USAEUR), and deployed the Brigade to Iraq. To help protect our troops and families on Lyme-endemic bases, Col. Swann is providing organizational insight and specific DOD operational guidance to refine implementation and ongoing monitoring plans.
To contact US BIOLOGIC, please email us at email@example.com.